Standard Biotools Inc.
LAB Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.60
KIRA · Stoqly’s AI analyst, in plain words
- Standard Biotools Inc. had $85.3M of revenue in fiscal 2025, down 6.2% on the year before. Over five years, revenue changed −9.2% a year on average.
- Its operating margin was −129.2%, up 10.9 pts: of every 100 in sales, about −129 is left after running the business.
- Standard Biotools Inc. lost $74.9M in fiscal 2025.
- Free cash flow was −$82.6M in fiscal 2025, −96.9% of revenue.
- Standard Biotools Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 8.0%.
Market cap
$235M
P/E
2.7x
Revenue
$85.3M
Net income
−$74.9M
Free cash flow
−$82.6M
Operating margin
−129.2%
Standard Biotools Inc. in 30 seconds · fiscal 2025
Are sales growing?
−6.2%
No. Sales fell 6.2% last year.
Does it make a profit?
−87.8%
No. It lost money last year.
Does profit turn into cash?
−96.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
2.7x
One share costs 2.7 times its yearly profit per share.
What Standard Biotools Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- STANDARD BIOTOOLS INC.
- CIK
- 0001162194
Standard Biotools Inc. · LAB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $131M | $97.9M | $106M | $91.0M | $85.3M |
| Revenue growth | −5.5% | −25.0% | 8.6% | −14.4% | −6.2% |
| Gross margin | — | 37.8% | 47.4% | 49.3% | 49.9% |
| Operating margin | −51.7% | −118.6% | −72.0% | −140.1% | −129.2% |
| Net income | −$59.2M | −$190M | −$74.7M | −$139M | −$74.9M |
| Net margin | −45.4% | −194.1% | −70.2% | −152.6% | −87.8% |
| Diluted EPS | −$0.78 | −$2.43 | −$0.94 | −$0.52 | −$0.20 |
| Cash | |||||
| Cash from operations | −$44.1M | −$89.4M | −$43.3M | −$143M | −$74.3M |
| Capital expenditure | $13.3M | $3.8M | $2.8M | $8.4M | $8.3M |
| Free cash flow | −$57.3M | −$93.2M | −$46.1M | −$152M | −$82.6M |
| FCF margin | −43.9% | −95.1% | −43.4% | −166.8% | −96.9% |
| Share buybacks | $0.0M | $0.6M | $5.4M | $40.5M | $0.0M |
| Share count change | 5.2% | 3.3% | 1.1% | 346.2% | 8.0% |
| Debt and strength | |||||
| Cash and short-term investments | $28.5M | $166M | $115M | $293M | $188M |
| Debt incl. finance leases | — | $64.9M | $63.5M | $0.3M | — |
| Shareholders' equity | $94.6M | −$81.5M | −$148M | $472M | $424M |
| Current ratio | 1.5x | 4.8x | 1.4x | 5.7x | 4.2x |
| Interest coverage | −17.6x | −26.8x | −16.8x | — | — |
| Returns and quality | |||||
| Return on capital | — | — | — | −56.2% | — |
| Return on equity | −50.7% | −2,895.8% | — | −85.8% | −16.7% |
| Return on tangible equity | — | — | — | −55.8% | −17.7% |
| Piotroski F-score | 2 | 2 | 4 | 4 | 4 |
| Altman Z'' | −9.3 | −7.5 | −11.7 | −0.9 | −1.4 |
Insiders bought, 12 months
$14.4M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Standard Biotools Inc. · LAB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.60 a share, the company is worth $235M: 2.7 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001162194). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.